Oral progestagens before menopause and breast cancer risk. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Breast Cancer Research and Treatment Year : 2007

Oral progestagens before menopause and breast cancer risk.


We examined the relationship between use of progestagen-only before menopause (except for mini-pills) after the age of 40 and invasive breast cancer risk in 73 664 women from the French E3N cohort study (mean age at start of follow-up, 51.8 years; mean duration of follow-up, 9.1 years). A total of 2390 cases of invasive breast cancer were diagnosed during follow-up. Risk estimates were calculated using the Cox proportional hazard model. Overall, ever use of progestagen before menopause was not significantly associated with risk (relative risk (RR): 1.01, 95% confidence interval: 0.93-1.11). However, we observed a significant increase in risk associated with the duration of use (P-value for trend: 0.012), current use of progestagens for longer than 4.5 years being significantly associated with risk (RR: 1.44, 95% confidence interval: 1.03-2.00). Prolonged use of progestagens after the age of 40 may be associated with an increased risk of breast cancer and the subject needs to be investigated further.
Fichier principal
Vignette du fichier
OralProgestagens-BJC.pdf (177.39 Ko) Télécharger le fichier

Dates and versions

inserm-00143656 , version 1 (15-10-2007)



Alban Fabre, Agnès Fournier, Sylvie Mesrine, Joëlle Desreux, Anne Gompel, et al.. Oral progestagens before menopause and breast cancer risk.. Breast Cancer Research and Treatment, 2007, 96 (5), pp.841-4. ⟨10.1038/sj.bjc.6603618⟩. ⟨inserm-00143656⟩
179 View
162 Download



Gmail Facebook Twitter LinkedIn More